Lack of Effect of 12-Week Treatment With Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients With Moderate to Severe Chronic Plaque Psoriasis
Clinical Pharmacokinetics - United Kingdom
doi 10.1007/s40262-018-0730-x
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 21, 2018
Authors
Publisher
Springer Science and Business Media LLC